Apixaban for the prevention of venous thromboembolism in acute medical illness
Status Suspended
Process STA pre-2018
Referral date 01 January 2010
Topic area
  • Cardiovascular

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager:


Technical Lead: TBC


Key events during the development of the guidance:

Date Update
20 March 2014

The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for apixaban in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

27 January 2012

Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance